Synthesis of Symmetrical and Unsymmetrical *N*,*N*'-Diaryl Guanidines via Copper/*N*-Methylglycine-Catalyzed Arylation of Guanidine Nitrate

Hui Xing,[†] Ye Zhang,[†] Yisheng Lai,^{*,†} Yongwen Jiang,[‡] and Dawei $Ma^{*,\ddagger}$

[†]State Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China [‡]State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Lu, Shanghai 200032, China

Supporting Information

ABSTRACT: CuI/*N*-methylglycine-catalyzed coupling reaction of guanidine nitrate with both aryl iodides and bromides takes place at 70–100 °C, affording symmetrical *N*,*N*'-diaryl guanidines with good to excellent yields. Unsymmetrical *N*,*N*'-diaryl guanidines can be assembled via monoarylation of guanidine nitrate with aryl iodides bearing a strong electron-withdrawing group and subsequent coupling with another aryl iodide.

In the past decade, great attention has been directed to ligand-promoted Ullmann-type coupling reactions.¹ These efforts not only provide mild conditions for coupling of aryl halides and nucleophiles, but also widen the reaction scope by using unusual nucleophiles, ¹ In terms of *N*-nucleophiles, sodium azide, ² ammonia, ³ *N*-acyl hydrazines, ^{3d,4} *N*-aryl ureas, ⁵ hydroxyamine derivatives⁶ and guanidines⁷ have been recently found to be suitable coupling partners. The CuI/N,Ndiethylsalicylamide-catalyzed N-arylation of guanidine nitrate reported by Antilla and co-workers offers a valuable method for preparing N,N'-diaryl guanidines,^{7d} which have been found to display some interesting biological activities such as binding with σ -receptors,⁸ blocking sodium channels,⁹ and antagonizing NMDA receptors.¹⁰ However, in Antilla and co-workers' studies only aryl iodides were examined, and reaction yields in many cases were below 50%.^{7d} Additionally, only symmetric N,N'-diaryl guanidines could be prepared using this method. Recently, we found that combination of CuI and Nmethylglycine¹¹ could catalyze the coupling reaction of guanidine nitrate with both aryl iodides and bromides, providing the corresponding symmetric N,N'-diaryl guanidines with good to excellent yields. By tuning the reaction sequence, we could assemble unsymmetric N,N-diaryl guanidines from guanidine nitrate and two different aryl iodides. Herein, we wish to disclose our results.

As shown in Table 1, we used reaction of 4-iodoanisole and guanidine nitrate as a model to explore optimized reaction conditions. Since Antilla and co-workers have described that L-proline was not a good ligand for their transformation,^{7d} we initially attempted to modify Antilla's conditions by changing ligand from L-proline to *trans*-4-hydroxy-L-proline. Such modification has been found to be effective for N-arylation of ammonia and Boc-protected hydrazine.^{3d} We were pleased that CuI/*trans*-4-hydroxy-L-proline-catalyzed reaction worked well in acetonitrile at 80 °C, affording diaryl guanidine **3a** in 84% yield (Table 1, entry 1). Changing the bidentate ligand¹ to



N,N-dimethylglycine gave a decreased yield (Table 1, entry 2). Similar results were observed in case of picolinic acid, 2methylquinolin-8-ol, and 2,2'-bipyridine as the ligands (Table 1, entries 4-6). However, the best result was obtained when Nmethylglycine was employed (Table 1, entry 3). The modification to the bases and solvents indicated that the best combination was K₃PO₄ and acetonitrile (Table 1, entries 7– 11). Switching Cu(I) salts from CuI to CuBr, CuCl, and Cu₂O gave inferior results (Table 1, entries 12-14). Further investigations revealed that there was no obvious loss in yield when catalyst loading was reduced to 5 mol % (Table 1, entry 15). At 5 mol % catalyst loading, reaction could complete even at 70 °C (Table 1, entry 16) but gave a decreased yield at 60 °C (Table 1, entry 17). Taken together, we concluded that the optimized conditions were using 5 mol % CuI and 10 mol % Nmethylglycine as the catalyst, K₃PO₄ as the base, acetonitrile as the solvent, and carrying out the reaction at 70 °C.

The established optimized reaction conditions were then examined by varying aryl halides. As summarized in Table 2, besides electron-rich aryl iodides (Table 2, entries 2–4), electron deficient aryl iodides were found to be applicable (Table 2, entries 5–8). A good yield were observed when relatively bulky 2-methyl iodobenzene was used, thereby giving a facile method for preparing the σ -receptor ligand N,N'-di-o-toylguanidine (DTG, 3e).⁸ Under the same reaction conditions, poor conversions were seen when aryl bromides were used. However, increasing the reaction temperatures to 90–100 °C and the catalyst loading of CuI to 10 mol % could provide satisfactory results (Table 2, entries 9–20). Although 2-bromopyridine was compatible with these conditions (Table 2, entry 20), no desired coupling products were isolated when other haloheteroarenes like 2-bromofuran, 2-bromothiophene,

Received:
 April 27, 2012

 Published:
 June 1, 2012

 Table 1. CuI-Catalyzed Coupling of Guanidine Nitrate with

 4-Iodoanisole under Different Conditions^a



^{*a*}Reaction conditions: 4-iodoanisole (1 mmol), guanidine nitrate (1 mmol), copper salt (0.1 mmol), ligand (0.2 mmol), base (6 mmol), solvent (5 mL), 8 h. ^{*b*}Isolated yield. ^{*c*}0.05 mmol of CuI and 0.1 mmol of *N*-methylglycine were used. ^{*d*}Reaction was performed at 70 °C. ^{*e*}Reaction was performed at 60 °C.

5-bromoindole, and 6-bromoindole were used. More studies are needed to solve this problem.

When 4-chlorophenyl iodide and methyl 4-iodobenzoate were used, some monoarylation products were isolated. This problem could be solved by decreasing the amount of guanidine nitrate to 0.5 equiv (Table 2, entries 7 and 8). It is easy to understand because after the first arylation, the electronwithdrawing groups in aromatic ring should make the resultant N-aryl guanidines less reactive. In this case excess guanidine nitrate could compete with N-aryl guanidines to make the coupling stop at the monoarylation stage. When more electrondeficient 4-nitroiodobenzene was employed under our standard conditions, N-(4-nitrophenyl)guanidine was found to be a major product, while diarylation product was isolated in a very low yield.

The poor ability of electron-deficient aryl halides for forming diarylation products inplied that we could develop a method to obtain unsymmetrical N,N'-diaryl guanidines via a sequential-controlled one-pot coupling reaction. The idea was to carry out the coupling of guanidine nitrate with aryl iodides bearing a strong withdrawing group first, and then add another aryl iodide for second coupling reaction. Accordingly, we conducted a coupling reaction of 4-nitroiodobenzene with guanidine nitrate at 70 °C. After 10 h, 4-iodoanisole was added for further coupling. As we desired, unsymmetrical N,N'-diaryl guanidine

Γable 2. Assembly of Symmetrical N,N-Diaryl Guanidines
via CuI/N-Methylglycine-Catalyzed Coupling of Aryl
Halides and Guanidine Nitrate ^a

ArX ¹ 1	guanidin 0-20 mol % ۸ 70 °C or 90-100	e nitrate, 5-10 mol % Cul /-methylglycine, K ₃ PO ₄ , Met C, 8 h (for aryl iodides) °C, 20 h (for aryl bromides)	$\stackrel{H}{\longrightarrow} \operatorname{Ar} \stackrel{H}{\longrightarrow} \operatorname{NH} \stackrel{H}{\longrightarrow} \operatorname{Ar}$
entry	Х	Ar	product (yield $(\%)^b$)
1	Ι	C ₆ H ₅	3b (90)
2	Ι	$4-CH_3C_6H_4$	3c (85)
3	Ι	$3-CH_3C_6H_4$	3d (88)
4	Ι	$2-CH_3C_6H_4$	$3e (81)^c$
5	Ι	$3,4-(F)_2C_6H_3$	3f (92)
6	Ι	4-CF ₃ C ₆ H ₄	3g (72)
7	Ι	4-ClC ₆ H ₄	3h $(72)^d$
8	Ι	4-MeO ₂ CC ₆ H ₄	3i $(65)^d$
9	Br	4-MeOC ₆ H ₄	3a (80)
10	Br	C ₆ H ₅	3b (81)
11	Br	$4-CH_3C_6H_4$	3c (78)
12	Br	$3-CH_3C_6H_4$	3d (77)
13	Br	$2-CH_3C_6H_4$	$3e (71)^c$
14	Br	2-naphthyl	3j (74)
15	Br	$4\text{-PhC}_6\text{H}_4$	$3\mathbf{k} (61)^e$
16	Br	4-MeSC ₆ H ₄	31 $(67)^e$
17	Br	3-ClC ₆ H ₄	3m (82)
18	Br	$3-FC_6H_4$	3n (85)
19	Br	$3-AcC_6H_4$	3o (75)
20	Br	2-pyridinyl	3p (72)

^{*a*}Reaction conditions: aryl halide (1 mmol), guanidine nitrate (1 mmol), CuI (0.05 mmol for entries 1–8, or 0.1 mmol for entries 9–20), *N*-methylglycine (0.1 mmol for entries 1–8, or 0.2 mmol for entries 9–20), K_3PO_4 (6 mmol), MeCN (5 mL), 70 °C, 8 h (for aryl iodides) or 90 °C, 20 h. (for aryl bromides). ^{*b*}Isolated yield. ^{*c*}2 mL of MeCN was used. ^{*d*}Reaction was performed with 1 mmol of aryl iodide and 0.5 mmol of guanidine nitrate. ^{*e*}Reaction was performed at 100 °C for 32 h.

4a was isolated in 69% yield after heating for 8 h (Table 3, entry 1). Using 3-methyliodobenzene for second coupling reaction gave a similar result (Table 3, entry 2). When sterically hindered 2-iodoanisole was employed, the desired product 4c was isolated in only 49% yield (Table 3, entry 3), presumably because in second coupling step both coupling partners are less reactive. Importantly, two electron-deficient aryl iodides could be utilized for second coupling (Table 3, entries 4 and 5), which would allow assembly of unsymmetrical N,N'-diaryl guanidines in a more diverse manner. Next, we attempted to use 3-nitroiodobenzene as a coupling starter and found that our sequential-controlled reaction procedure was still reliable, although slightly low yields were obtained (Table 3, entries 6-8). The similar results were observed when 1-(4iodophenyl)ethanone (Table 3, entry 9) and methyl 4iodobenzoate (Table 3, entry 10) were employed as the coupling starters. Noteworthy is that in these reactions, the corresponding symmetrical N,N'-diaryl guanidines were still isolated as the minor products. Although more condition studies are required to minimize the side reactions, our method is still comparable with those reported^{9,10,12} previously because of its convenient operation and use of commercially available starting materials and inexpensive reagents.

The detailed mechanism for this transformation is still unclear. However, we proposed a possible catalytic cycle as outlined in Scheme 1. It is known that *N*-methylglycine and Table 3. One-Pot Synthesis of Unsymmetrical N,N'-Diarylguanidines^a



^{*a*}Reaction conditions: aryl iodide (1 mmol), guanidine nitrate (1 mmol), CuI (0.1 mmol), *N*-methylglycine (0.2 mmol), K_3PO_4 (6 mmol), MeCN (5 mL), 70 °C, 10 h, and then another aryl iodide (1 mmol), 8 h. ^{*b*}Isolated yield. ^cSecond coupling was performed at 90 °C for 12 h.

Scheme 1



CuI could form the chelate A, which might coordinate with guanidine (or *N*-arylguanidine 2) to give the complex B. Oxidative addition of B to aryl halide could deliver the Cu(III) complex C, which was reacted with base to afford the complex D. Reductive elimination of D would produce 2 (or 4) and regenerate the Cu(I) complex A.

In a conclusion, we have revealed that *N*-methylglycine is an effective ligand for promoting CuI-catalyzed direct arylation of guanidine. A number of functionalized aryl iodides and aryl bromides could be employed as the coupling partners, affording the corresponding symmetrical N,N'-diaryl guanidines with great diversity. When aryl iodides bearing a strong electron-withdrawing group were used, the reaction could be stopped at the monoarylation stage, and the resultant coupling products could couple with another aryl iodide in situ to afford unsymmetrical N,N'-diaryl guanidines. Thus, our method provides a valuable and alternative approach for preparing N,N'-diaryl guanidines.

EXPERIMENTAL SECTION

General Procedure for Synthesis of Symmetrical *N*,*N*'-Diarylguanidines. A Schlenk tube was charged with aryl halides (1.0 mmol), guanidine nitrate (1.0 mmol), *N*-methylgycine (8.9 mg, 0.1 mmol (for aryl iodides) or 17.8 mg, 0.2 mmol (for aryl bromides)), recrystallized CuI (9.5 mg, 0.05 mmol (for aryl iodides) or 19.0 mg, 0.1 mmol (for aryl bromides)), and K_3PO_4 (1.27 g, 6 mmol). The tube was evacuated and backfilled with argon before MeCN (5 mL) was added. The reaction mixture was stirred at the indicated temperatures until the corresponding aryl halide was completely consumed as monitored by TLC. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with water and brine and dried over Na₂SO₄. Removal of solvent in vacuo followed by purification with column chromatography on silica gel (50:1–20:1 methylene chloride/methanol as eluent) provided the desired product.

1,3-Bis(4-methoxyphenyl)guanidine (3a). 122 mg (90% yield), white solid: mp 154–156 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.02 (d, J = 8.7 Hz, 4H), 6.83 (d, J = 8.4 Hz, 4H), 5.16 (br s, 2H), 3.77 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 155.9 (2C), 151.1, 136.7 (2C), 124.7 (4C), 114.6 (4C), 55.4 (2C); ESI-MS m/z 272.4 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₈N₃O₂ (M + H)⁺ 272.1393, found 272.1391.

1,3-Diphenylguanidine (3b). 95 mg (90% yield), white solid: mp 147–149 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.33–7.26 (m, 4H), 7.13-7.04 (m, 6H), 4.74 (br s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 143.6 (2C), 129.3 (4C), 123.2 (2C), 122.9 (4C); ESI-MS *m/z* 212.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₃H₁₄N₃ (M + H)⁺ 212.1182, found 212.1186.

1,3-Di-*p***-tolylguanidine (3c).** 102 mg (85% yield), white solid: mp 128–130 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.11 (d, *J* = 8.1 Hz, 4H), 7.00 (d, *J* = 8.4 Hz, 4H), 4.80 (br, s, 3H), 2.31 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.5, 140.4 (2C), 133.1 (2C), 130.0 (4C), 123.3 (4C), 20.8 (2C); ESI-MS *m*/*z* 240.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₇N₃ (M + H)⁺ 240.1495, found 240.1492.

1,3-Di-*m***-tolylguanidine (3d).** 105 mg (88% yield), white solid: mp 99–101 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.19 (t, J = 7.2 Hz, 2H), 6.93–6.86 (m, 6H), 4.82 (br s, 3H), 2.29 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 143.6 (2C), 139.2 (2C), 129.2 (2C), 124.1 (2C), 123.8 (2C), 119.9 (2C), 21.4 (2C); ESI-MS *m*/*z* 240.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₇N₃ (M + H)⁺ 240.1495, found 240.1492.

1,3-Di-o-tolylguanidine (3e). 97 mg (81% yield), white solid: mp 177–178 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.16–6.99 (m, 8H), 5.78 (br s, 3H), 2.20 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.3, 140.3 (2C), 132.9 (2C), 130.9 (2C), 126.9 (2C), 124.93 (2C), 124.85 (2C), 17.9 (2C); ESI-MS *m*/*z* 240.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₇N₃ (M + H)⁺ 240.1495, found 240.1500.

1,3-Bis(3,4-diffuorophenyl)guanidine (3f). 130 mg (92% yield), white solid: mp 1554–156 °C; ¹H NMR (300 MHz, CD₃OD) δ 7.21–7.08 (m, 4H), 6.89–6.85 (m, 2H); ¹³C NMR (100 MHz, CD₃OD) δ 151.3 (dd, 2C, *J* = 243.5, 13.8 Hz), 152.4, 147.0 (dd, 2C, *J* = 239.1, 13.1 Hz), 142.8 (d, 2C, *J* = 6.6 Hz), 118.5 (dd, 2C, *J* = 5.1, 2.9 Hz), 117.9 (d, 2C, *J* = 16.8 Hz), 111.6 (d, 2C, *J* = 18.9 Hz); ESI-MS *m/z* 284.2 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₃H₁₀F₄N₃ (M + H)⁺ 284.0805, found 284.0802.

1,3-Bis(4-(trifluoromethyl)phenyl)guanidine (3g). 125 mg (72% yield), white solid: mp 107–109 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.48 (d, *J* = 8.4 Hz, 4 H), 7.22 (d, *J* = 8.4 Hz, 4 H), 6.54 (br s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 140.4 (2C), 128.1 (q, 2C, *J* = 32.1 Hz), 126.9 (q, 4C, *J* = 3.6 Hz), 123.7 (q, 2C, *J* = 270.5 Hz), 123.3 (4C); ESI-MS *m*/*z* 348.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₂F₆N₃ (M + H)⁺ 348.0929, found 348.0920.

1,3-Bis(4-chlorophenyl)guanidine (3h). 101 mg (72% yield), white solid: mp 138–140 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.33 (d, *J* = 8.7 Hz, 4H), 7.17 (d, *J* = 8.4 Hz, 4H), 6.64 (br s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 153.9, 135.4 (2C), 130.2 (2C), 129.5 (4C), 125.8 (4C); ESI-MS *m*/*z* 279.9 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₃H₁₁Cl₂N₃ (M + H)⁺ 280.0393, found 280.0387.

Dimethyl 4,4'-((Iminomethylene)bis(azanediyl))dibenzoate (**3i**). 106 mg (65% yield), white solid: mp 166–168 °C; ¹H NMR (400 MHz, CD₃OD) δ 8.06 (d, *J* = 8.4 Hz, 4H), 7.42 (d, *J* = 8.8 Hz, 4H), 3.90 (s, 6H); ¹³C NMR (100 MHz, CD₃OD) δ 167.6 (2C), 154.5, 143.4 (2C), 131.9 (4C), 128.1 (2C), 123.7 (4C), 52.5 (2C); ESI-MS *m*/*z* 328.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₇H₁₈N₃O₄ (M + H)⁺ 328.1292, found 328.1296.

1,3-Di(naphthalen-2-yl)guanidine (3j). 115 mg (74% yield), white solid: mp 125–127 °C; ¹H NMR (300 MHz, CD₃OD) δ 7.99 (d, J = 8.7 Hz, 2H), 7.92–7.89 (m, 6H), 7.55–7.48 (m, 6H); ¹³C NMR (100 MHz, CD₃OD) δ 156.4, 135.0 (2C), 133.7 (2C), 133.5 (2C), 130.9 (2C), 128.7 (2C), 128.6 (2C), 127.9 (2C), 127.4 (2C), 124.2 (2C), 124.1 (2C); ESI-MS m/z 312.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₂₁H₁₈N₃ (M + H)⁺ 312.1495, found 312.1506.

1,3-Di([1,1'-biphenyl]-4-yl)guanidine (3k). 111 mg (61% yield), white solid: mp 218–220 °C; ¹H NMR (300 MHz, CD₃OD) δ 7.75 (d, J = 8.7 Hz, 4H), 7.65 (d, J = 7.5 Hz, 4H), 7.48–7.43 (m, 8H), 7.39–7.34 (m, 2H); ¹³C NMR (100 MHz, CD₃OD) δ 156.2, 141.4 (2C), 141.0 (2C), 135.6 (2C), 129.8 (4C), 129.3 (4C), 128.6 (2C), 127.7 (4C), 126.3 (4C); ESI-MS *m*/*z* 364.1 (M + H) +; FT-HRMS (ESI) calcd for C₂₅H₂₂N₃ (M + H) + 364.1808, found 364.1806.

1,3-Bis(4-(methylthio)phenyl)guanidine (3l). 102 mg (67% yield), colorless oil: ¹H NMR (300 MHz, CDCl₃) δ 7.22 (d, *J* = 8.7 Hz, 4H), 7.15 (d, *J* = 8.7 Hz, 4H), 2.45 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 152.3, 136.1 (2C), 135.4 (2C), 128.2 (4C), 124.5 (4C), 16.4 (2C); ESI-MS *m*/*z* 304.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₈N₃S₂ (M + H)⁺ 304.0937, found 304.0940.

1,3-Bis(3-chlorophenyl)guanidine (3m). 115 mg (82% yield), white solid: mp 145–147 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.22 (t, *J* = 7.8 Hz, 2H), 7.13 (t, *J* = 1.8 Hz, 4H), 7.05–6.96 (m, 4H), 4.55 (br s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 152.1, 146.9 (2C), 135.3 (2C), 131.0 (2C), 123.1 (2C), 122.6 (2C), 120.9 (2C); ESI-MS *m/z* 280.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₃H₁₂Cl₂N₃ (M + H)⁺ 280.0403, found 280.0402.

1,3-Bis(3-fuorophenyl)guanidine (3n). 105 mg (85% yield), white solid: mp 119–121 °C; ¹H NMR (300 MHz, CD₃OD) δ 7.35–7.28 (m, 2H), 7.09–6.99 (m, 4H), 6.80 (td, *J* = 8.4, 2.1 Hz, 2H); ¹³C NMR (100 MHz, CD₃OD) δ 165.8 (d, 2C, *J* = 242.1 Hz), 153.1, 145.1 (d, 2C, *J* = 10.2 Hz), 131.4 (d, 2C, *J* = 9.5 Hz), 119.07 (d, 2C, *J* = 2.2 Hz), 111.07 (d, 2C, *J* = 21.9 Hz), 110.5 (d, 2C, *J* = 24.1 Hz); ESI-MS *m*/*z* 248.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₃H₁₂F₂N₃ (M + H)⁺ 248.0994, found 248.0983.

1,3-Bis(3-acetylphenyl)guanidine (30). 110 mg (75% yield), white solid: mp 147–149 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.68 (s, 2H), 7.61 (d, *J* = 7.5 Hz, 2H), 7.47–7.36 (m, 4H), 4.51 (br s, 3H), 2.55 (s, 6H); ¹³C NMR (100 MHz, CD₃OD) δ 200.4 (2C), 152.4, 145.9 (2C), 139.0 (2C), 130.2 (2C), 127.8 (2C), 123.4 (2C), 122.5 (2C), 26.6 (2C); ESI-MS *m*/*z* 296.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₇H₁₈N₃O₂ (M + H)⁺ 296.1393, found 296.1393.

1,3-Di(pyridin-2-yl)guanidine (3p). 77 mg (72% yield), white solid: mp 144–146 °C; ¹H NMR (400 MHz, CD₃OD) δ 8.42 (dd, *J* = 5.2, 1.2 Hz, 2H), 7.92 (td, *J* = 8.0, 2.0 Hz, 2H), 7.27–7.24 (m, 2H), 7.22 (d, *J* = 6.3 Hz, 2H); ¹³C NMR (100 MHz, CD₃OD) δ 154.3, 153.1 (2C), 147.6 (2C), 140.8 (2C), 121.2 (2C), 115.1 (2C); ESI-MS *m*/*z* 214.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₁H₁₂N₅ (M + H)⁺ 214.1087, found 214.1089.

General Procedure for Synthesis of Unsymmetrical N,N'-Diarylguanidines. A Schlenk tube was charged with aryl iodide (1.0 mmol), guanidine nitrate (1.0 mmol), N-methylgycine (17.8 mg, 0.2 mmol), recrystallized CuI (19.0 mg, 0.1 mmol), and K₃PO₄ (1.27 g, 6 mmol). The tube was evacuated and backfilled with argon before MeCN (5 mL) was added. The reaction mixture was stirred at 70 °C for 10 h before another aryl iodide (1 mmol) was added. After the resultant mixture was heated at 70 °C for 8–12 h, it was extracted with ethyl acetate. The organic layer was washed with water and brine and dried over Na₂SO₄. Removal of solvent in vacuo followed by purification with column chromatography on silica gel (50:1–20:1 methylene chloride/methanol as eluent) provided the corresponding product.

1-(4-Methoxyphenyl)-3-(4-nitrophenyl)guanidine (4a). 197 mg (69% yield), yellow solid: mp 181–183 °C; ¹H NMR (300 MHz, CD₃OD) δ 8.13 (d, *J* = 9.3 Hz, 2H), 7.26 (d, *J* = 9.3 Hz, 2H), 7.14 (d, *J* = 9.0 Hz, 2H), 6.88 (d, *J* = 8.7 Hz, 2H), 3.76 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 157.6, 155.6, 153.3, 142.5, 135.8, 125.8 (2C), 125.0 (2C), 122.4 (2C), 115.3 (2C), 55.7; ESI-MS *m/z* 287.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₄H₁₅N₄O₃ (M + H)⁺ 287.1139, found 287.1140.

1-(4-Nitrophenyl)-3-(*m***-tolyl)guanidine (4b).** 189 mg (70% yield), yellow solid: mp 182–184 °C; ¹H NMR (300 MHz, CD₃OD) δ 8.13 (d, *J* = 9.0 Hz, 2H), 7.28 (d, *J* = 9.0 Hz, 2H), 7.16 (t, *J* = 7.8 Hz, 1H), 7.04–6.99 (m, 2H), 6.85 (d, *J* = 7.5 Hz, 1H), 2.30 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 155.1, 152.3, 143.6, 142.5, 139.8, 129.7 (2C), 125.8 (2C), 124.7, 123.3, 122.2, 119.8, 21.3; ESI-MS *m/z* 271.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₄H₁₅N₄O₂ (M + H)⁺ 271.1189, found 271.1190.

1-(2-Methoxyphenyl)-3-(4-nitrophenyl)guanidine (4c). 140 mg (49% yield), yellow solid: mp 153–155 °C; ¹H NMR (300 MHz, CD₃OD) δ 8.22 (d, *J* = 8.7 Hz, 2H), 7.45–7.38 (m, 3H), 7.22 (t, *J* = 7.8 Hz, 1H), 7.09 (d, *J* = 7.8 Hz, 1H), 6.97 (t, *J* = 8.0 Hz, 1H), 3.91 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 155.4, 154.6, 146.6, 145.4, 129.3, 127.3, 126.0 (2C), 125.8, 123.9 (2C), 122.0, 113.1, 56.2; ESI-MS *m*/*z* 287.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₄H₁₅N₄O₃ (M + H)⁺ 287.1139, found 287.1147.

1-(4-Chlorophenyl)-3-(4-nitrophenyl)guanidine (4d). 180 mg (62% yield), yellow solid: mp 95–97 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.17 (d, *J* = 9.0 Hz, 2H), 7.31 (d, *J* = 8.7 Hz, 2H), 7.21 (d, *J* = 9.0 Hz, 2H), 7.13 (d, *J* = 8.7 Hz, 2H), 3.89 (br s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 151.6, 142.7, 130.4, 129.8, 129.8 (2C), 128.4, 125.8 (2C), 123.9 (2C), 121.7 (2C); ESI-MS *m*/*z* 291.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₃H₁₂ClN₄O₂ (M + H)⁺ 291.0643, found 291.0645.

Methyl 4-(3-(4-Nitrophenyl)guanidino)benzoate (4e). 201 mg (64% yield), yellow solid: mp 220–222 °C; ¹H NMR (300 MHz, CD₃OD) δ 8.20 (d, *J* = 8.4 Hz, 2H), 7.97 (d, *J* = 8.1 Hz, 2H), 7.38 (t, *J* = 7.2 Hz, 4H), 3.88 (s, 3H); ¹³C NMR (100 MHz, acetone-d₆) δ 167.0, 148.7, 142.3, 131.2 (2C), 126.0, 125.6 (2C), 123.9, 121.5 (2C), 120.7 (2C), 115.8, 51.8.; ESI-MS *m*/*z* 315.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₅H₁₅N₄O₄ (M + H)⁺ 315.1089, found 315.1093.

1-(4-Methoxyphenyl)-3-(3-nitrophenyl)guanidine (4f). 151 mg (55% yield), yellow solid: mp 105–107 °C; ¹H NMR (300 MHz, CD₃OD) δ 8.19 (s, 1H), 8.14 (d, *J* = 5.7 Hz, 1H), 7.73–7.65 (m, 2H), 7.29 (d, *J* = 9.0 Hz, 2H), 7.02 (d, *J* = 9.0 Hz, 2H), 3.82 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 159.7, 155.6, 150.2, 141.9, 131.5, 131.1, 130.6, 127.3 (2C), 120.7, 119.7, 115.8 (2C), 55.8; ESI-MS *m*/*z* 287.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₄H₁₅N₄O₃ (M + H)⁺ 287.1139, found 287.1140.

1-(3-Nitrophenyl)-3-(m-tolyl)guanidine (4g). 159 mg (59% yield), yellow solid: mp 163–165 °C; ¹H NMR (400 MHz, CD₃OD) δ 8.14 (t, *J* = 1.8 Hz, 1H), 8.05 (dt, *J* = 7.6, 2.0 Hz, 1H), 7.67–7.60 (m, 2H), 7.29 (t, *J* = 7.8 Hz, 1H), 7.16 (s, 1H), 7.13–7.07 (m, 2H), 2.36 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 152.7, 150.2, 149.6, 143.4, 139.8, 130.6, 129.7, 129.4, 124.6, 123.4, 119.8, 117.6, 117.0, 21.3; ESI-MS *m*/*z* 271.0 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₄H₁₅N₄O₂ (M + H)⁺ 271.1190, found 271.1193.

1-(3-Nitrophenyl)-3-(3-(trifluoromethyl)phenyl)guanidine (**4h**). 162 mg (50% yield), yellow solid: mp 90–92 °C; ¹H NMR (400 MHz, CD₃OD) δ 8.10 (t, *J* = 2.0 Hz, 1H), 8.09–7.83 (m, 1H), 7.59 (s, 1H), 7.56–7.46 (m, 4H), 7.29 (d, *J* = 6.8 Hz, 1H); ¹³C NMR (100 MHz, CD₃OD) δ 154.6, 150.2, 142.0, 140.8, 132.7 (q, 1C, *J* = 32.1 Hz), 131.4, 131.3, 130.5, 127.9, 125.1 (q, 1C, *J* = 269.8 Hz), 122.7 (q, 1C, *J* = 3.6 Hz), 121.1 (q, 1C, *J* = 3.7 Hz), 120.5, 119.1; ESI-MS *m*/*z* 325.0 (M + H)⁺; FT-HRMS (ESI) calcd for $C_{14}H_{12}F_3N_4O_2$ (M + H)⁺ 325.0907, found 325.0904.

1-(4-Acetylphenyl)-3-(4-methoxyphenyl)guanidine (4i). 172 mg (61% yield), white solid: mp 153–155 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, *J* = 9.0 Hz, 2H), 7.12 (dd, *J* = 8.7, 1.5 Hz, 4H), 6.87 (d, *J* = 9.0 Hz, 2H), 4.45 (br s, 3H), 3.79 (s, 3H), 2.55 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 199.5, 157.3, 152.8, 152.7, 136.9, 131.4, 130.9 (2C), 124.9 (2C), 121.9 (2C), 115.3 (2C), 55.7, 26.1; ESI-MS

The Journal of Organic Chemistry

m/z 284.1 (M + H)+; FT-HRMS (ESI) calcd for $C_{16} \rm H_{18} N_3 O_2$ (M + H)+ 284.1394, found 284.1400.

Methyl 4-(3-(4-Methoxyphenyl)guanidino)benzoate (4j). 170 mg (57% yield), white solid: mp 192–194 °C; ¹H NMR (300 MHz, CD₃OD) δ 8.09 (d, *J* = 8.7 Hz, 2H), 7.44 (d, *J* = 8.7 Hz, 2H), 7.29 (d, *J* = 9.0 Hz, 2H), 7.03 (d, *J* = 8.7 Hz, 2H), 3.91 (s, 3H), 3.83 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 167.5, 160.6, 156.3, 141.3, 132.1 (2C), 129.2, 128.2, 128.1 (2C), 124.6 (2C), 116.1 (2C), 55.8, 52.6; ESI-MS *m*/*z* 300.1 (M + H)⁺; FT-HRMS (ESI) calcd for C₁₆H₁₈N₃O₃ (M + H)⁺ 300.1343, found 300.1352.

ASSOCIATED CONTENT

S Supporting Information

Copies of ¹H NMR and ¹³C NMR spectra for all new products. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: Madw@mail.sioc.ac.cn; lcpu333@yahoo.com.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors are grateful to the Chinese Academy of Sciences, National Natural Science Foundation of China (Grant 20621062 & 20572119) and Ministry of Science & Technology (Grant 2009CB940900) for their financial support.

REFERENCES

 (1) For recent reviews, see: (a) Evano, G.; Blanchard, N.; Toumi, M. Chem. Rev. 2008, 108, 3054. (b) Ma, D.; Cai, Q. Acc. Chem. Res. 2008, 41, 1450. (c) Monnier, F.; Taillefer, M. Angew. Chem., Int. Ed. 2009, 48, 6954. (d) Surry, D. S.; Buchwald, S. L. Chem. Sci. 2010, 13.
 (e) Sperotto, E.; Klink, G. P. M.; Koten, G.; Vries, J. G. Dalton Trans. 2010, 39, 10338.

(2) (a) Zhu, W.; Ma, D. Chem. Commun. 2004, 888. (b) Andersen, J.;
Madsen, U.; Bjorkling, F.; Liang, X. F. Synlett 2005, 2209.
(c) Markiewicz, J.; Wiest, O.; Helquist, P. J. Org. Chem. 2010, 75, 4887.

(3) Kim, J.; Chang, S. Chem. Commun. 2008, 3052. (b) Kaddouri, H.; Vicente, V.; Ouali, A.; Ouazzani, F.; Taillefer, M. Angew. Chem., Int. Ed. 2008, 48, 333. (c) Ntaganda, R.; Dhudshia, B.; Macdonald, C. L. B.; Thadani, A. N. Chem. Commun. 2008, 6200. (d) Jiang, L.; Lu, X.; Zhang, H.; Jiang, Y.; Ma, D. J. Org. Chem. 2009, 74, 4542. (e) Wang, D.; Cai, Q.; Ding, K. Adv. Synth. Catal. 2009, 351, 1722. (f) Thakur, K. G.; Ganapathy, D.; Sekar, G. Chem. Commun. 2011, 47, 5076.

(4) Wolter, M.; Klapars, A.; Buchwald, S. L. Org. Lett. 2001, 3, 3803.
(b) Lam, M. S.; Lee, H. W.; Chan, A. S. C.; Kwong, F. Y. Tetrahedron Lett. 2008, 49, 6192.

(5) Hosseinzadeh, R.; Sarrafi, Y.; Mohadjerani, M.; Mohammadpourmir, F. *Tetrahedron Lett.* **2008**, *49*, 840.

(6) Jones, K. L.; Porzelle, A.; Hall, A.; Woodrow, M. D.; Tomkinson, N. C. O. Org. Lett. **2008**, *10*, 797.

(7) (a) Evindar, G.; Batey, R. A. Org. Lett. 2003, 5, 133. (b) Deng, X.;
McAllister, H.; Mani, N. S. J. Org. Chem. 2009, 74, 5742. (c) Yang, X.;
Liu, H.; Fu, H.; Qiao, R.; Jiang, Y.; Zhao, Y. Synlett 2010, 1, 101.
(d) Cortes-Salva, M.; Nguyen, B.-L.; Cuevas, J.; Pennypacker, K. R.;
Antilla, J. C. Org. Lett. 2010, 12, 1316. (e) Hammoud, H.; Schmitt, M.;
Bihel, F.; Antheaume, C.; Bourguignon, J.-J. J. Org. Chem. 2012, 77,
417. (f) Rauws, T. R. M.; Maes, B. U. W. Chem. Soc. Rev. 2012, 41,

(8) Weber, E.; Sonder, M.; Quarum, M.; McLean, S.; Pou, S.; Keana, J. F. W. Proc. Natl. Acad. Sci. U. S. A. **1986**, 83, 8784.

(9) Reddy, N. L.; Fan, W.; Magar, S. S.; Perlman, M. E.; Yost, E.; Zhang, L.; Berlove, D.; Fischer, J. B.; Burke-Howie, K.; Wolcott, T.; Durant, G. J. J. Med. Chem. **1998**, 41, 3298.

(10) (a) Reddy, N. L.; Hu, L.-Y.; Cotter, R. E.; Fischer, J. B.; Wong, W. J.; McBurney, R. N.; Weber, E.; Holmes, D. L.; Wong, S. T.; Prasad, R.; Keana, J. F. W. *J. Med. Chem.* **1994**, *37*, 260. (b) Hu, L.-Y.; Guo, J.; Magar, S. S.; Fischer, J. B.; Burke-Howie, K. J.; Durant, G. J. *J. Med. Chem.* **1997**, *40*, 4281.

(11) Ma, D.; Cai, Q.; Zhang, H. Org. Lett. 2003, 5, 2453. (b) Zhang, H.; Cai, Q.; Ma, D. J. Org. Chem. 2005, 70, 5164.

(12) For a review, see: Katritzky, A. R.; Rogovoy, B. V. ARKIVOC 2005, vi, 49.